stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Return on invested capital
Neurocrine Biosciences, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 17.7%, down 4.2 percentage points from fiscal 2025 (21.8%). Over the past ten years it has ranged from −1,131.0% (fiscal 2016) to 84.6% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 21.8% | (1.73) |
| FY2024 | 23.6% | 10.50 |
| FY2023 | 13.1% | (8.60) |
| FY2022 | 21.7% | 15.24 |
| FY2021 | 6.42% | (9.42) |
| FY2020 | 15.8% | (68.78) |
| FY2019 | 84.6% | 74.09 |
| FY2018 | 10.5% | 46.89 |
| FY2017 | −36.4% | 1,094.63 |
| FY2016 | −1,131.0% | (1,005.95) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 57.7% |
| UTHR United Therapeutics Corporation compare | 30.1% |
| ZTS Zoetis Inc. compare | 19.6% |
| NBIX Neurocrine Biosciences, Inc. | 17.7% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.77% |
| ALKS Alkermes plc compare | 1.54% |
| ELAN Elanco Animal Health Incorporated compare | 0.51% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. compare | −0.02% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement